If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 105.00
Bid: 102.00
Ask: 108.00
Change: 0.00 (0.00%)
Spread: 6.00 (5.882%)
Open: 105.00
High: 105.00
Low: 105.00
Prev. Close: 105.00
IGP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

8 Apr 2010 07:00

RNS Number : 8639J
Intercede Group PLC
08 April 2010
 



8 April 2010

Intercede Group plc

("Intercede")

 

Trading Update for the Full Year to 31 March 2010

 

We are pleased to report that Intercede is continuing to experience growth in sales revenues, pre-exceptional operating profit and cash.

 

Revenues for the year ended 31 March 2010 are expected to be approximately 10% ahead of the previous year's reported revenues of £5.7m. This is a strong performance in a difficult economic market. However, with sales slightly below expectations and having maintained our planned investment for the growth of the business, the pre-exceptional operating profit for the year (2009: £1.9m) will be ahead of last year but lower than market expectations.

 

Cash balances at 31 March 2010 total £4.7m which compares to £3.7m at 31 March 2009.

 

As previously announced, the US and UK patent litigations involving ActivIdentity were settled on 23 March 2010. The exceptional charge to the current financial year for all of the legal fees and associated costs relating to this case is expected to be in the region of £1.5m. No further legal costs are expected to arise and, as previously advised, it is not anticipated that the patent license agreement included within the settlement will have a material impact on Intercede's current or future earnings.

 

Intercede Chairman and Chief Executive Richard Parris said:

 

 "I am pleased to report an improved trading performance against a backdrop of the increasing adoption of our technology by national governments, managed service providers and large enterprise customers. Our increasing market penetration has not only provided financial returns in the current period but is also creating annuity revenue streams for the future."

 

Intercede expects to announce its full year results for the year ended 31 March 2010 by mid June 2010.

 

About Intercede

 

Intercede is the producer of the MyID® Identity and Credential Management System (IDCMS). Intercede's MyID is the only IDCMS software product that enables organizations to easily and securely manage the identities of people and their associated identity credentials within a single, integrated, workflow driven platform. This includes enabling and managing: secure registration, biometric capture, application vetting and approval through to smart card personalisation, issuance and management.

 

Intercede's MyID is being used around the world by large corporations, governments and banks to manage millions of identities for employees, citizens and customers. Notable deployments in the US include 10 Federal Agencies, a program with Lockheed Martin and two major US financial institutions. In Europe and the Middle East, Intercede's MyID is being deployed in support of government identity, health and corporate employee ID security projects.

 

For more information visit http://www.intercede.com

 

ENQUIRIES

Intercede Group plc

Richard Parris, Chairman & Chief Executive

Andrew Walker, Finance Director

Tel. +44 (0)1455 558111

FinnCap

Clive Carver- Corporate Finance

Joanna Weaving - Corporate Broking

Tel. +44 (0)20 7600 1658

Pelham Bell Pottinger

Archie Berens / Francesca Tuckett

Tel. +44 (0)20 7337 1509

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTSSWEFWFSSELL
Date   Source Headline
14th Apr 20207:00 amRNSDirector/PDMR Shareholding
7th Apr 20207:00 amRNSTrading Update
3rd Apr 20205:07 pmRNSShare Incentive Plan
31st Mar 20207:00 amRNSReceipt of $4.6m Order
28th Feb 20207:00 amRNSShare Incentive Plan
26th Feb 20209:50 amRNSShare Incentive Plan
25th Feb 20207:00 amRNSShare Incentive Plan
12th Feb 202011:22 amRNSShare Award
25th Nov 20197:00 amRNSHalf-year Report
7th Oct 20197:00 amRNSTrading Update
30th Sep 20197:00 amRNSDirector/PDMR Shareholding
18th Sep 20196:30 pmRNSResult of AGM
16th Sep 20193:56 pmRNSPosting of Annual Report & Notice of AGM
17th Jun 20197:00 amRNSAppointment of Non-Executive Director
5th Jun 20197:00 amRNSFinal Results
8th Apr 20197:00 amRNSSale of Property
2nd Apr 20197:00 amRNSTrading Update
28th Feb 20197:00 amRNSNew Contract Win
4th Feb 20193:19 pmRNSHolding(s) in Company
17th Dec 201810:19 amRNSBoard Change
26th Nov 20187:00 amRNSHalf-year Report
22nd Oct 20187:00 amRNSGrant of Options
4th Oct 20187:00 amRNSTrading Statement
20th Sep 20187:00 amRNSResult of AGM
4th Sep 20187:00 amRNSDirector/PDMR Shareholding
10th Aug 20187:00 amRNSDirector/PDMR Shareholding
31st Jul 20187:00 amRNSDirector/PDMR Shareholding
10th Jul 20188:00 amRNSDirector/PDMR Shareholding
29th Jun 20184:59 pmRNSPDMR Shareholding
7th Jun 20187:00 amRNSFinal Results
26th Apr 20182:10 pmRNSPDMR Change
25th Apr 20187:00 amRNSDirector/PDMR Shareholding
20th Apr 201812:15 pmRNSPDMR Change
11th Apr 201811:36 amRNSHolding(s) in Company
11th Apr 20187:00 amRNSAppointment of Chief Executive
4th Apr 20187:00 amRNSReceipt of $4.0m Order/Trading Update
29th Mar 20187:00 amRNSDirectorate Change
9th Mar 20187:00 amRNSNew Contract Award
13th Feb 20187:00 amRNSNew Contract Award
4th Dec 20177:00 amRNSContract
30th Nov 20177:00 amRNSNew Contract Award
27th Nov 20177:00 amRNSHalf-year Report
6th Nov 20171:58 pmRNSTrading Update
26th Oct 20177:00 amRNSShare Award
5th Oct 20177:00 amRNSTrading Statement
13th Sep 20173:30 pmRNSResult of AGM
13th Sep 20177:00 amRNSDirectorate Change
25th Aug 20177:00 amRNSIssue of Convertible Loan Notes
1st Aug 20179:07 amRNSTotal Voting Rights
27th Jul 20177:00 amRNSShare Incentive Plan & Issue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.